The Federal Government Just Funded Its First Psychedelics Moonshot

For decades, the federal government's relationship with psychedelic research could be summarized in a single word: no. Schedule I classification, the War on Drugs, and institutional inertia kept psilocybin, LSD, and their chemical cousins locked out of the federal funding ecosystem even as academic researchers accumulated evidence of their therapeutic potential. That era ended on April 24, 2026, when ARPA-H announced 13 research teams selected for its $139.4 million EVIDENT initiative — the largest federal investment in psychedelic-adjacent therapeutics in American history.

EVIDENT — Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health — doesn't just fund psychedelics research. It funds the infrastructure to prove whether psychedelics actually work, for whom, and why. The distinction matters enormously. ARPA-H isn't betting $139 million that psilocybin cures depression. It's betting that objective biomarkers can replace the subjective self-report scales that have kept psychiatry stuck in a pre-precision-medicine era for 70 years.

What EVIDENT Actually Funds

The initiative operates across four technical areas that together define a roadmap for precision psychiatry:

TA1: What should we measure? Identifying which objective biomarkers — blood proteins, brain activity patterns, gut microbiome composition, wearable sensor data — actually predict treatment response. Current psychiatric assessment relies almost entirely on patient self-report ("On a scale of 1-10, how depressed do you feel?"). EVIDENT wants to replace this with measurements as objective as a blood glucose reading.

TA2: What happens during treatment? Tracking physiological changes in real-time during therapeutic interventions, whether that's a psilocybin session, transcranial magnetic stimulation, or a digital therapeutic. The goal is to know within hours — not weeks — whether a treatment is working for a specific patient.

TA3: Who responds to which treatment? Building predictive models that match patients to the therapies most likely to help them, based on their individual biology rather than population averages. This is the precision-medicine promise applied to mental health.

TA4: What shared data foundation enables all of the above? Creating the multimodal, longitudinal datasets that don't currently exist because psychiatric research has been siloed across institutions with incompatible data formats.

The 13 Teams and What They're Actually Doing

The first cohort spans universities, startups, and research institutions — a deliberately diverse portfolio designed to generate complementary data rather than redundant findings.

Johns Hopkins University School of Medicine brings data from eight completed psilocybin clinical trials across multiple psychiatric conditions. This is the single richest dataset on psilocybin's clinical effects that exists anywhere, and EVIDENT is funding its integration with biomarker data that wasn't collected during the original trials.

University of Wisconsin-Madison is running three psilocybin trials designed to answer a question that has divided the field: does the therapeutic benefit of psilocybin come from the conscious psychedelic experience itself, or from the neurobiological changes that happen independently of subjective awareness? They're also testing transcutaneous vagal nerve stimulation as an augmentation strategy.

University of Southern California is studying psilocybin combined with mindfulness training in healthy adults — a feasibility study that could establish baseline neuroplasticity signatures before testing in clinical populations.

Diamond Therapeutics (Toronto) and Tactical Mind Research Coalition (St. Petersburg, FL) are contributing data from a Phase 2a clinical trial of psilocybin for generalized anxiety disorder — one of the conditions where traditional treatments have the highest failure rates.

Yale Stress Center is running a pregnenolone intervention trial for alcohol use disorder, targeting the neurosteroid pathway rather than the serotonergic pathway that psychedelics affect. This provides a critical comparator: same precision-measurement approach, different therapeutic mechanism.

INVI MindHealth (Denver) is building a real-time biomarker platform that integrates data from both neuromodulation and psychedelic therapy sessions. Their system aims to provide clinicians with objective, moment-by-moment feedback during treatment — a capability that doesn't exist in current clinical practice.

Duke University is measuring saliva biomarkers — cortisol, estradiol, IL-6, and IL-1β — to track stress physiology and inflammation during therapeutic interventions. Saliva collection is non-invasive and cheap, making it scalable in ways that blood draws and brain imaging are not.

Holobiome (Boston) is studying microbiome-modulating interventions targeting the gut-brain axis. The connection between gut bacteria and mental health is one of the most active areas of neuroscience research, and EVIDENT is funding the first systematic attempt to link microbiome changes to psychiatric treatment outcomes.

NeuroFlow (Philadelphia) is building a population-scale framework that evaluates rapid-acting interventions against real-world clinical baselines — essentially creating the comparison standard that every other EVIDENT team's data will be measured against.

Alden Scientific (Cambridge, MA), Attune Neurosciences (San Francisco), Motif Neurotech (Houston), and Ksana Health (Eugene, OR) round out the cohort with capabilities in multi-omics analysis, low-intensity focused ultrasound, neuromodulation measurement, and wearable-EHR integration, respectively.

The $50 Million Psychedelics Carve-Out

Buried in the EVIDENT announcement is a provision that may prove more consequential than the research awards themselves: at least $50 million will be allocated to match state government investments in psychedelic research for populations with serious mental illness. This matching-fund mechanism creates a federal-state partnership structure for psychedelics research that has no precedent.

Several states — Oregon, Colorado, and others — have already legalized or decriminalized psilocybin for therapeutic use. The $50 million matching provision means that state-level investments in psychedelic therapy infrastructure now unlock federal dollars, creating a flywheel effect. A state that commits $5 million to psilocybin research for treatment-resistant PTSD can potentially access a proportional federal match, making the economics of state-level psychedelic programs dramatically more favorable.

ARPA-H uses the term "neuroplastogens" rather than "psychedelics" in official communications — a deliberate framing choice that emphasizes mechanism of action (promoting neural plasticity) over cultural baggage. The compounds eligible for study include ketamine, ibogaine, psilocybin, LSD, DMT, and scopolamine.

The Executive Order Connection

EVIDENT exists because President Trump signed an Executive Order to Accelerate Medical Treatments for Serious Mental Illness. The political logic is straightforward: the administration needs a tangible response to the mental health crisis, particularly among veterans and rural populations that are core constituencies. Psychedelics offer the rare combination of bipartisan appeal (libertarian right meets progressive left) and genuine clinical promise that makes them politically viable in a way that expanded Medicaid coverage or community mental health center funding is not.

The executive order gives ARPA-H the mandate and the political cover to fund research that would have been unthinkable five years ago. It also signals that FDA pathway clearance — the ultimate goal for any therapeutic — has high-level political support. For research teams and companies in the psychedelics space, this represents a fundamental change in the regulatory risk calculus.

What This Means for Research Teams Not Yet Selected

ARPA-H has explicitly stated that "future award announcements under the EVIDENT initiative will be made on a rolling basis." This is not a closed competition — it's an ongoing program that will continue to make investments as new teams and data sources become available. Organizations with relevant capabilities should be monitoring the EVIDENT initiative page for future funding opportunities.

The most competitive future applicants will likely be those who can contribute datasets from completed or ongoing clinical trials — the initiative's core constraint is data availability, not analytical capability. If your organization has conducted controlled trials of rapid-acting therapeutics (psychedelic or otherwise) and collected biomarker data alongside clinical outcomes, you have something EVIDENT needs.

Research institutions in states with active psychedelic therapy programs are particularly well-positioned for the $50 million matching-fund component. Building relationships with state health departments now — before the matching criteria are published — creates a structural advantage when the solicitation opens.

The EVIDENT initiative represents a paradigm shift in how the federal government approaches mental health research. Rather than funding individual drug development programs and hoping they produce FDA-approvable therapies, ARPA-H is building the measurement infrastructure that makes all future behavioral health therapeutics provable. That's a bet on scientific infrastructure over specific compounds — and for researchers positioned at the intersection of biomarkers, data science, and clinical psychiatry, it opens funding pathways that didn't exist six months ago. Platforms like Granted can help teams identify where their existing capabilities intersect with EVIDENT's technical areas and craft proposals that speak directly to the program's precision-measurement mandate.